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abstract
PURPOSE Patients with advanced endometrial carcinoma have limited treatment options. We report final primary
efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus
pembrolizumab in an ongoing phase Ib/II study of selected solid tumors.
METHODS Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200mg intravenously once every
3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORRWk24);
secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall
survival (OS). Tumor assessments were evaluated by investigators per immune-related RECIST.
RESULTS At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with
a median follow-up of 18.7 months. The ORRWk24 was 38.0% (95% CI, 28.8% to 47.8%). Among subgroups,
the ORRWk24 (95% CI) was 63.6% (30.8% to 89.1%) in patients with microsatellite instability (MSI)–high tumors
(n = 11) and 36.2% (26.5% to 46.7%) in patients with microsatellite-stable tumors (n = 94). For previously
treated patients, regardless of tumor MSI status, the median DOR was 21.2 months (95% CI, 7.6 months to not
estimable), median PFS was 7.4 months (95% CI, 5.3 to 8.7 months), and median OS was 16.7 months
(15.0 months to not estimable). Grade 3 or 4 treatment-related adverse events occurred in 83/124 (66.9%)
patients.
CONCLUSION Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced
endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of
tumor MSI status. The combination therapy had a manageable toxicity profile.
J Clin Oncol 38:2981-2992. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
The incidence and disease-related mortality of en-
dometrial cancer, the most common gynecologic
cancer in the United States, continues to increase.1-4
Although early-stage endometrial carcinoma is asso-
ciated with a favorable 5-year relative survival rate
(96%),5 the rate is 18% in patients with distant
metastases.5
Paclitaxel plus carboplatin is standard first-line treat-
ment of advanced, recurrent, and metastatic en-
dometrial carcinoma.6,7 Until recently, only 2 other
therapies were specifically approved in the metastatic
setting.8 Megestrol acetate is approved for the pallia-
tive treatment of advanced endometrial carcinoma,
regardless of platinum use.9 Pembrolizumab, a mono-
clonal antibody targeting programmed death receptor-1
(PD-1), is broadly (ie, tissue agnostic) approved for
microsatellite instability–high (MSI-H)/mismatch-
repair–deficient (dMMR) solid tumors that have
progressed after prior therapy and have no satis-
factory alternative treatment options.10 Accordingly,
pembrolizumab is used for metastatic MSI-H endome-
trial carcinoma after front-line chemotherapy failure.
MSI-H tumors with high mutational burdens are more
susceptible to checkpoint inhibitors,11 and the mu-
tational burden in MSI-H endometrial cancers is
particularly high.12 Pembrolizumab has demonstrated
efficacy in patients with MSI-H endometrial cancer. In
a phase II study of pembrolizumab monotherapy in
patients with previously treated advanced MSI-H/
dMMR noncolorectal cancer, results from the endo-
metrial cohort (n = 49) demonstrated an objective
response rate (ORR) of 57.1% (95% CI, 42.2%
to 71.2%), with a median progression-free survival
(PFS) of 25.7 months (95% CI, 4.9 months to not
reached).13,14 However, MSI-H endometrial cancers
comprise only 16% of recurrent disease cases.15
In a phase Ib study of pembrolizumab for ad-
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endometrial cancer (in patients whose disease progressed
after standard therapy or for whom standard therapy was
not appropriate), 18 of 19 patients with evaluable tumor
samples had microsatellite-stable (MSS) cancer.16 For all
patients in the efficacy analysis (n = 23), the ORR was
13% (95% CI, 2.8% to 33.6%), with median PFS of
1.8 months (95% CI, 1.6 to 2.7 months), suggesting that
pembrolizumab monotherapy may be less effective in
patients with MSS tumors.
Lenvatinib is an oral multikinase inhibitor that targets
vascular endothelial growth factor receptors 1-3, fibroblast
growth factor receptors 1-4, platelet-derived growth factor
receptor-a, RET, and KIT.17-19 In a phase II study of len-
vatinib monotherapy for advanced, previously treated en-
dometrial cancer, the ORR was 14.3% (as assessed by
independent imaging review [IIR] per RECIST version
1.120), and the median PFS was 5.4 months.21
The combination of immune checkpoint inhibitors with
lenvatinib has been evaluated in preclinical mouse xeno-
graft studies.22-24 In these studies, lenvatinib plus PD-1/PD-
L1 signal inhibitors had more potent antitumor activity than
either agent alone.22-24 KEYNOTE-146/Study 111 (a phase
Ib/II study) evaluated this combination in patients with
advanced tumors.25 In an interim cohort analysis (activity
data cutoff: December 15, 2017; median study follow-up:
13 months) of patients with advanced endometrial cancer
who were selected regardless of PD-L1 status, histology, or
tumor MSI status, lenvatinib plus pembrolizumab dem-
onstrated promising efficacy: objective response at week
24, assessed using immune-related RECIST (irRECIST),
was achieved by 39.6% of the 53 patients (investigator
assessment; 45.3%, IIR).26 Here we present the final pri-
mary efficacy analysis results of the cohort of patients from
KEYNOTE-146/Study 111 with advanced endometrial
cancer.
METHODS
Study Design and Patients
KEYNOTE-146/Study 111 is an ongoing multinational,
open-label, single-arm study (ClinicalTrials.gov identifier:
NCT02501096) of lenvatinib plus pembrolizumab in pa-
tients with selected solid tumors (ie, non–small-cell lung
cancer, renal cell carcinoma, endometrial carcinoma,
urothelial carcinoma, squamous cell carcinoma of the head
and neck, or melanoma). Eligibility criteria for the endo-
metrial cohort have been published,26 and a brief overview
is provided in the Data Supplement.
This study was conducted in accordance with the guide-
lines of Good Clinical Practice (defined by the International
Council on Harmonization) and the principles of the
Declaration of Helsinki; the protocol was approved by the
institutional review board or ethics committee at each
participating center, and all patients provided written in-
formed consent.











Age, years, mean (SD) 65.4 (7.42) 62.4 (9.45) 65.1 (7.60) 65.3 (7.83)
Race
White 81 (86.2) 9 (81.8) 93 (86.1) 108 (87.1)
Black or African
American
6 (6.4) 0 6 (5.6) 7 (5.6)
Asian 4 (4.3) 1 (9.1) 5 (4.6) 5 (4.0)
American Indian or
Alaskan Native




0 1 (9.1) 1 (0.9) 1 (0.8)
Other 2 (2.1) 0 2 (1.9) 2 (1.6)
ECOG PS
0 49 (52.1) 1 (9.1) 53 (49.1) 62 (50.0)




46 (48.9) 8 (72.7) 55 (50.9) 67 (54.0)
FIGO grade 1 10 (10.6) 2 (18.2) 12 (11.1) 15 (12.1)
FIGO grade 2 15 (16.0) 4 (36.4) 19 (17.6) 22 (17.7)
FIGO grade 3 21 (22.3) 2 (18.2) 24 (22.2) 30 (24.2)
Serous
adenocarcinoma
33 (35.1) 0 35 (32.4) 39 (31.5)
Clear-cell
adenocarcinoma




0 1 (9.1) 1 (0.9) 1 (0.8)
Adenocarcinoma, not
otherwise specified
1 (1.1) 0 1 (0.9) 1 (0.8)
Otherc 9 (9.6) 1 (9.1) 10 (9.3) 10 (8.1)
PD-L1 statusd
Positive 46 (48.9) 7 (63.6) 53 (49.1) 60 (48.4)
Negative 39 (41.5) 4 (36.4) 43 (39.8) 52 (41.9)





0 0 0 0 9 (7.3)
1 48 (51.1) 7 (63.6) 57 (52.8) 60 (48.4)
2 36 (38.3) 3 (27.3) 40 (37.0) 43 (34.7)
$ 3 10 (10.6) 1 (9.1) 11 (10.2) 12 (9.7)
(continued on following page)
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Procedures and Study End Points
On the basis of the phase Ib dose-finding results,25 patients
were administered lenvatinib 20 mg once daily orally and
pembrolizumab 200mg intravenously once every 3 weeks in
3-week cycles (maximum of 35 pembrolizumab treatments).
The primary end point in this study was ORR at week 24
(ORRWK24). Responses were confirmed by a second as-
sessment $ 4 weeks after initial response. Secondary end
points included ORR, duration of response (DOR), PFS,
overall survival (OS), disease control rate (DCR; defined as
the proportion of patients with a best overall response of
complete response [CR], partial response [PR], or stable
disease), and clinical benefit rate (CBR; defined as the
proportion of patients with CR, PR, or durable stable dis-
ease [defined as stable disease $ 23 weeks]). Tumor re-
sponses for primary and secondary end points were
assessed by the investigator per irRECIST.27
Prespecified exploratory end points included tumor re-
sponses per irRECIST27 and RECIST version 1.120 by IIR
(assessed by BioTel Research, BioTelemetry), and antitu-
mor activity according to PD-L1 status. Activity by tumor
histology andMSI status were post hoc exploratory analyses.
Adverse events (AEs) were assessed according to Common
Terminology Criteria for Adverse Events version 4.03.
For all patients, tumor assessments (investigator assess-
ment and IIR) were completed at baseline, every 6 weeks
for the first 24 weeks, and every 9 weeks thereafter. PD-L1
status was determined using an investigational version of
the PD-L1 immunochemistry 22C3pharmDx28 and a pro-
visional combined positive score (defined as the number of
staining tumor and immune cells relative to total tumor
cells) cutoff of 1. Central testing to determine MSI was
conducted using the MSI Analysis System, and central
testing for mismatch repair (MMR) status was conducted
using the Ventana MMR Immunohistochemical Assay.
Available data regarding known MSI/MMR status based on
local testing per institutional guidelines was also collected.
Toxicity was managed by supportive medications, treatment
interruption, dose reduction (lenvatinib only; re-escalation
was not allowed), and/or treatment discontinuation in ac-
cordance with predefined dose-modification guidelines.
Information regarding treatment discontinuation of either
lenvatinib or pembrolizumab and patient assessments
during the follow-up period of this study can be found in the
Data Supplement.
Statistical Methods
The phase II portion was designed to expand to 20 patients
with endometrial cancer on the basis of efficacy and safety
results. A protocol amendment allowed further expansion to
a total sample size of ~120 patients after predetermined
criteria of 2 interim analyses were met. Details regarding
sample size determination can be found in the Data
Supplement.
Efficacy analyses focused on patients who previously re-
ceived systemic treatment; the primary analysis was
planned for patients from the full analysis set who com-
pleted 8 cycles of treatment and had week 24 tumor as-
sessments or who had discontinued early because of
progressive disease, unacceptable toxicity, withdrawn
consent, or study termination by the sponsor at the time of
data cutoff. According to an addendum to the statistical
analyses (made before database lock), data cutoff was
when $ 100 patients with histologically confirmed, pre-
viously treated endometrial carcinoma had sufficient follow-
up to provide a median follow-up of $ 12 months, and
$ 6 months of follow-up after initial objective response for
all responders.
Additional efficacy analyses are reported for previously
treated and treatment-naı̈ve patients (Data Supplement),
regardless of their follow-up time at data cutoff. These
efficacy analyses were based on the intention-to-treat
population (ie, all patients with endometrial cancer who
entered the study treatment period). Safety analyses were











No. of patients previously
treated with
bevacizumab









92 (97.9) 11 (100.0) 106 (98.1) 113 (91.1)
Other anticancer
combinations
9 (9.6) 1 (9.1) 11 (10.2) 12 (9.7)
Monotherapy 33 (35.1) 3 (27.3) 36 (33.3) 37 (29.8)
Prior history of/current
hypertension
60 (63.8) 9 (81.8) 71 (65.7) 79 (63.7)
NOTE. Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CPS, combined positive score; dMMR, mismatch-repair deficient;
EC, endometrial carcinoma; ECOG PS, Eastern Cooperative Oncology Group
performance status; FIGO, International Federation of Gynecology and Obstetrics;
MSI-H, microsatellite instability high; MSI/MMR, microsatellite instability/mismatch
repair; PD-L1, programmed death-ligand 1; pMMR, mismatch-repair proficient;
SD, standard deviation.
aEnrolled before July 1, 2018.
bThree patients had an unknown MSI/MMR tumor status.
cPredominantly mixed histology.
dPD-L1 status is positive if CPS is $ 1 and negative if CPS is , 1.
eThe majority of patients received therapies in the adjuvant or metastatic setting;
9 patients received therapy in the neoadjuvant setting; the setting for 2 patients was
unknown.
fPatients may be counted in multiple categories.
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TABLE 2. Summary of Tumor Response as Assessed by Investigators per Immune-Related RECIST
Response Category
Previously Treated ECa









Complete response 2 (2.1) 1 (9.1) 3 (2.8) 3 (2.4)
Partial response 32 (34.0) 6 (54.5) 38 (35.2) 46 (37.1)
Stable disease 45 (47.9) 3 (27.3) 50 (46.3) 56 (45.2)
Progressive disease 10 (10.6) 1 (9.1) 12 (11.1) 13 (10.5)
Not evaluable 5 (5.3) 0 5 (4.6) 6 (4.8)
Objective response rate (complete response + partial response) 34 (36.2) 7 (63.6) 41 (38.0) 49 (39.5)
95% CI 26.5 to 46.7 30.8 to 89.1 28.8 to 47.8 30.9 to 48.7
At data cutoff
Best overall response
Complete response 7 (7.4) 1 (9.1) 8 (7.4) 8 (6.5)
Partial response 28 (29.8) 6 (54.5) 34 (31.5) 42 (33.9)
Stable disease 44 (46.8) 3 (27.3) 49 (45.4) 55 (44.4)
Progressive disease 10 (10.6) 1 (9.1) 12 (11.1) 13 (10.5)
Not evaluable 5 (5.3) 0 5 (4.6) 6 (4.8)
Objective response rate (complete response + partial response) 35 (37.2) 7 (63.6) 42 (38.9) 50 (40.3)
95% CI 27.5 to 47.8 30.8 to 89.1 29.7 to 48.7 31.6 to 49.5
Disease control rate 79 (84.0) 10 (90.9) 91 (84.3) 105 (84.7)
95% CI 75.0 to 90.8 58.7 to 99.8 76.0 to 90.6 77.1 to 90.5
Clinical benefit rate 55 (58.5) 8 (72.7) 63 (58.3) 73 (58.9)
95% CI 47.9 to 68.6 39.0 to 94.0 48.5 to 67.7 49.7 to 67.6
Duration of response, months
Median (95% CI) NE (7.4 to NE) 21.2 (7.3 to NE) 21.2 (7.6 to NE) NE (8.5 to NE)
No. of patients with duration of response, probability, Kaplan-
Meier estimate
$ 6 months 25 7 32 36
Probability (95% CI) 0.85 (0.67 to 0.93) 1.00 (NE to NE) 0.87 (0.72 to 0.95) 0.87 (0.73 to 0.94)
$ 12 months 9 3 12 12
Probability (95% CI) 0.60 (0.39 to 0.75) 0.80 (0.20 to 0.97) 0.63 (0.45 to 0.77) 0.65 (0.47 to 0.78)
Time to response, months, mean (SD) 2.5 (1.53) 2.9 (1.84) 2.6 (1.57) 2.5 (1.51)
Maximum tumor shrinkage in sum of diameters of target lesions,
%, n/mb
. 0 75/89 (84.3) 8/10 (80.0) 86/102 (84.3) 101/117 (86.3)
$ 50 25/89 (28.1) 6/10 (60.0) 31/102 (30.4) 36/117 (30.8)
$ 75 11/89 (12.4) 2/10 (20.0) 13/102 (12.7) 16/117 (13.7)
NOTE. Data are presented as No. (%) unless otherwise indicated.
Abbreviations: dMMR, mismatch-repair deficient; EC, endometrial carcinoma; MSI-H, microsatellite instability-high; MSI/MMR, microsatellite instability/
mismatch repair; MSS, microsatellite stable; NE, not estimable; pMMR, mismatch-repair proficient; SD, standard deviation.
aEnrolled before July 1, 2018; 3 patients had an unknown MSI/MMR tumor status.
bm is the number of patients with both baseline and post-baseline sum of diameters of target lesions and is used as the denominator for the respective
percentages.
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based on the safety set, defined as all patients (previously
treated and treatment naı̈ve) who received any amount of
study drug, irrespective of their follow-up time at data
cutoff. The most common treatment-related AEs were re-
ported by preferred terms or “baskets” (ie, groups of related
preferred terms). Treatment-emergent prespecified AEs,
serious treatment-related AEs, and deaths were reported by
preferred terms.
Statistical analyses were performed using SAS (SAS In-
stitute) version 9.4. ORRWK24 and the exact 95% CIs were
calculated with the Clopper-Pearson method, as were 95%
CIs for ORR, DCR, and CBR. Patients who did not have an
evaluable tumor assessment were included in the de-
nominator for the calculation of ORR. Medians of PFS and
OS (and their median follow-up times) and DOR were
estimated with the Kaplan-Meier method, and 95%
CIs were calculated with a generalized Brookmeyer and
Crowley method. Probabilities of patients achieving a DOR
$ 6 months or $ 12 months were calculated using the




When enrollment (starting September 10, 2015) reached
118 patients (July 1, 2018), end-of-enrollment notifications
were sent to study sites. At the time of notification, 7 ad-
ditional patients who had completed screening were
allowed to enroll in the endometrial carcinoma cohort (Data
Supplement). Of the 125 enrolled patients, 1 had a major
protocol violation—her primary tumor was determined to be
a uterine leiomyosarcoma.
Analysis of the primary end point focused on the 108
patients with endometrial carcinoma who enrolled before
July 1, 2018 and had previously received systemic therapy;
these patients met all previously described conditions for
the primary analysis at time of data cutoff (January 10,
2019; Data Supplement). The median follow-up for these
patients was 18.7 months (95% CI, 13.1 to 20.3 months),
and 29 (26.9%) patients were receiving ongoing study
treatment with at least 1 study drug at data cutoff. The most
common histologic subtypes of disease were endometrioid
adenocarcinoma (50.9%; International Federation of Gy-
necology and Obstetrics [FIGO] grade 1 or 2, 28.7%; FIGO
grade 3, 22.2%) and serous carcinoma (32.4%; Table 1).
Nearly half (49.1%) of the patients were PD-L1 positive.
Ninety-four (87.0%) and 11 (10.2%) patients were MSS
or MMR proficient (pMMR) and MSI-H or dMMR, re-
spectively (Table 1).
Efficacy
The primary end point, ORRWK24, was 38.0% (41/108
patients; 95% CI, 28.8% to 47.8%; Table 2). In the 102
patients with evaluable tumor assessments by investigators
per irRECIST, the sum of diameters of target lesions
decreased (any size) from baseline in 86 (84.3%) patients
(Fig 1; Table 2); 31 (30.4%) had a maximum decrease of
$ 50%and 13 (12.7%) had amaximumdecrease of$ 75%
(Table 2).
Regarding secondary end points, the ORR of patients
previously treated for endometrial carcinoma was 38.9%
(42/108, 95% CI, 29.7% to 48.7%; CR, 8/108, 7.4%, 95%
CI, 3.3% to 14.1%; PR, 34/108, 31.5%, 95% CI, 22.9% to
41.1%) and the median DOR was 21.2 months (95% CI,
7.6 months to not estimable [NE]; Table 2; Fig 2A). Among
responders, the Kaplan-Meier estimate of the probability of
a DOR $ 6 months was 87% (95% CI, 72% to 95%),
and the Kaplan-Meier estimate of the probability of a DOR
$ 12 months was 63% (95% CI, 45% to 77%; Table 2).
Median PFS was 7.4 months (95% CI, 5.3 to 8.7 months;
median follow-up: 11.9months; 95%CI, 9.9 to 18.4months;
Fig 2B) and median OS was 16.7 months (95% CI,
15.0 months to NE; Fig 2C).
Tumor responses were similar irrespective of investigator or
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MSI/MMR status: Non–MSI-H/pMMR MSI-H/dMMR Not available
























FIG 1. Percentage change in sum of
diameters of target lesions from baseline
to post-baseline nadir by microsatellite
instability/mismatch-repair (MSI/MMR)
status (by investigator assessment; using
immune-related RECIST). dMMR, MMR
deficient; m, the number of previously
treated patients with both baseline and
at least 1 postbaseline target lesion as-
sessment; MSI-H, MSI-high; pMMR,
MMR proficient; PD-1, programmed
death receptor-1; PD-L1, programmed
death-ligand 1.
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note, 35.8% (19/53; 95% CI, 23.1% to 50.2%) of patients
with PD-L1–positive tumors and 39.5% (17/43; 95% CI,
25.0% to 55.6%) of patients with PD-L1–negative tumors
had objective responses by investigator assessment per
irRECIST (Data Supplement). For patients with MSS/pMMR
tumors, ORR—as assessed by investigators per irRECIST—
was 37.2% (35/94; 95% CI, 27.5% to 47.8%). For patients
with MSI-H/dMMR tumors, ORR was 63.6% (7/11; 95%CI,
30.8% to 89.1%; Table 2). Median DOR was NE (95% CI,
7.4 months to NE) for patients with MSS/pMMR tumors and
B
Total Failed Censored
108 70 38 7.4 (5.3 to 8.7)
94 62 32 7.4 (5.0 to 7.6)
11 6 5 18.9 (4.0 to NE)































Total in EC 2L+ 108 105 88 80 69 61 53 52 37 35 25 22 16 16 15 15 13 13 13 10 9 8 8 8 8 7 7 6 6 6 6 5 4 3 3 2 2 1 1 0
MSS/pMMR 94 91 76 69 59 52 45 44 30 29 20 18 13 13 12 10 10 10 10 8 7 6 6 6 6 5 5 5 5 5 5 4 3 2 2 1 1 0 0 0
MSI-H/dMMR 11 11 10 10 10 9 8 8 7 6 5 4 3 3 3 3 3 3 3 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 0
A


















Total in EC 2L+ 42 42 41 37 37 36 32 26 21 17 15 12 12 12 12 11 11 9 9 8 7 7 6 6 66 6 5 5 5 4 3 2 2 1 1 0
35 35 34 30 30 29 25 21 17 14 12 9 9 9 9 8 8 7 7 6 5 5 5 5 5 5 5 4 4 4 3 2 1 1 0 0 0MSS/pMMR























21.2 (7.6 to NE)
NE (7.4 to NE)
21.2 (7.3 to NE)
Median, months (95% CI)
No. at risk:
No. at risk:
Median, months (95% CI)
FIG 2. Kaplan-Meier plot of (A) duration of response, (B) progression-free survival, and (C) overall survival assessed by the investigator per immune-
related RECIST (for A and B groups only; not appropriate for C) in patients with endometrial cancer previously treated with systemic therapies. dMMR,
mismatch-repair deficient; EC 2L1, endometrial cancer second-line (or greater) treatment MSI-H, microsatellite instability high; MSS, microsatellite
stable; NE, not estimable; pMMR, mismatch-repair proficient.
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21.2 months (95% CI, 7.3 months to NE) for patients with
MSI-H/dMMR tumors (Table 2; Fig 2A). Details regarding
median PFS and OS by tumor MSI status are shown in
Figures 2B and 2C, respectively. Additional details of re-
sponses by MSI and PD-L1 status are shown in the Data
Supplement; the percentage changes in the sums of di-
ameters of target lesions at post-baseline nadir by histologic
subtype are shown in Figure 3 (by investigator assessment;
using irRECIST) and the Data Supplement (by IIR; using
RECIST version 1.1). Tumor responses by histologic sub-
types are shown in the Data Supplement.
Safety
Meanduration of treatmentwith lenvatinib plus pembrolizumab
was 8.5 months (8.2 months, lenvatinib and 7.3 months,
pembrolizumab). Any-grade treatment-related AEs oc-
curred in 120 (96.8%) patients. Grade 3 or 4 treatment-
related AEs occurred in 83 (66.9%) patients (Table 3).
Overall, 22 (17.7%) patients discontinued 1 or both study
drugs because of treatment-related AEs (19 [15.3%]
discontinued lenvatinib, 15 [12.1%] discontinued
pembrolizumab, and 11 [8.9%] discontinued both study
drugs). Treatment-related AEs led to dose interruptions of
lenvatinib and/or pembrolizumab in 87 (70.2%) patients
and dose reductions of lenvatinib in 78 (62.9%) patients.
The mean dose intensity of lenvatinib was 14.4 mg/day
(standard deviation [SD], 4.3), and the mean dose of
lenvatinib received as a percentage of the planned dose
was 71.9% (SD, 21.4). The mean duration of treatment
with lenvatinib at each dose level is reported in the Data
Supplement; 11 (8.9%) patients remained on lenvatinib for
$ 6 months after cycle 1 day 1 with no dose reductions.
The most common any-grade treatment-related AEs and
the most common grade 3 or 4 treatment-related AEs are
reported in Table 3 and the Data Supplement, respectively.
Seventy-one patients (57.3%) experienced treatment-
emergent, prespecified AEs associated with pembrolizumab.
Hypothyroidism was the most frequent of these AEs,
occurring in 59 (47.6%) patients.
Serious treatment-related AEs are reported in the Data
Supplement. Fifty-one deaths occurred during this study:
16 while receiving study drug and 35 during follow-up—
with a median time from last dose to death of 171 days
(29/35 patients discontinued because of radiologic progres-
sion; cause of death during follow-up was not recorded). Of
note, 4 deaths were considered caused by treatment-
emergent AEs (1 each due to GI perforation, intestinal
obstruction, general physical health deterioration, and
metabolic encephalopathy) not deemed treatment related,
and 2 deaths were judged to be treatment related (1 due to
sepsis caused by an Escherichia coli infection and 1 due to
intracranial hemorrhage).
DISCUSSION
Advanced endometrial carcinomas have a poor prognosis;
the continued annual increase in incidence and disease-
related mortality of endometrial cancer1,3,29 underscores
a dire need to improve therapeutics for this malignancy.
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FIG 2. (Continued).
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Nearly 84% of patients with recurrent endometrial carci-
noma have MSS or microsatellite-indeterminate tumors.15
Although pembrolizumab is effective for MSI-H disease
(objective response, 28/49 [57.1%] patients),13,14 it ap-
pears less effective for MSS disease (best response was
PR, 2/18 patients).16 Similarly, in advanced/recurrent pre-
viously treated endometrial carcinoma, investigational PD-1
monoclonal antibody dostarlimab (formerly TSR-042) had
greater efficacy in patients with MSI-H tumors compared
with patients with MSS tumors (ORR, [confirmed and un-
confirmed responses] 50.0% and 19.1%, respectively).30
ORRs observed with other investigational PD-L1 monoclonal
antibodies have had similar trends in previously treated
endometrial cancer (avelumab: 27%, patients with dMMR
tumors; 6%, patients with pMMR tumors; durvalumab: 43%,
patients with dMMR tumors; 3%, patients with pMMR
tumors).31,32 Moreover, antiangiogenic and antimicrotubule
medications have limited efficacy (ORR, 14%-16%; median
PFS, 3.4-4.2 months) in recurrent/advanced endometrial
carcinoma.33,34
Our study had comparable results (ORRWK24, 38.0%; ORR,
38.9%; median PFS, 7.4 months in patients with previously
treated endometrial cancer) to the recently published in-
terim analysis of lenvatinib plus pembrolizumab in endo-
metrial cancer (ORRWK24, 39.6%; ORR, 39.6%; median
PFS, 7.4 months)26 but with a longer follow-up time; as
such, this suggests that the combination of lenvatinib plus
pembrolizumab has favorable efficacy compared with that of
previously reported therapies in similar populations.30,33,34
Importantly, tumor responses in our study were similar
regardless of the tumor response criteria used and
whether evaluated by investigator or IIR. Lenvatinib plus
pembrolizumab also demonstrated a robust depth of
response; 84% of patients with evaluable tumor assessments
had decreased tumor lesions (any size) from baseline, and
30% had a maximum decrease of $ 50%. Even more
compelling, ORR in patients with difficult-to-treat MSS
disease was 37.2%. Although the mechanistic basis for the
encouraging efficacy of lenvatinib plus pembrolizumab in
advanced endometrial carcinoma requires additional
study, experimental models indicate lenvatinib modulates
cancer immunity by decreasing the suppressive tumor-
associated macrophage population,22,35 which may
allow T cells reinvigorated by pembrolizumab to have
enhanced antitumor activity.
The safety profile of lenvatinib plus pembrolizumab was
generally similar to previously reported profiles of each
monotherapy (lenvatinib, 24 mg/d; pembrolizumab,
10 mg/kg every 2 or 3 weeks).13,14,16,21,36-38 Although hy-
pothyroidism occurred in a greater proportion of patients in
our study than in previous reports of either monotherapy
(48% [treatment-related, 43%] v# 37%, respectively),36,37
there was only 1 occurrence of grade 3 hypothyroidism.
Overall, the rate of grade 3/4 treatment-related AEs was
similar in our study to the interim analysis of lenvatinib
plus pembrolizumab in endometrial cancer (67% v 68%,
respectively).26 Timely identification of treatment-related
AEs and their management throughout this study with
dose interruptions and reductions may have facilitated
treatment continuation, as only 17.7% of patients dis-
continued study treatment(s) because of treatment-
related AEs. On average, patients received 11 pem-
brolizumab treatments, with only 4 patients reaching the































FIG 3. Percentage change in sum of diameters of target lesions from baseline to post-baseline nadir by histologic subtype (by investigator
assessment; using immune-related RECIST). m, the number of previously treated patients with both baseline and at least 1 postbaseline target
lesion assessment.
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TABLE 3. Treatment-Related Adverse Events ($ 20% any grade or any grade 3 or grade 4 events)
Preferred Term or Basket
Previously Treated ECa (n = 108) All EC (N = 124)
Any Grade Grade 3/4 Any Grade Grade 3/4
Patients with any treatment-related TEAEs 105 (97.2) 75 (69.4) 120 (96.8) 83 (66.9)
Hypertensionb 66 (61.1) 35 (32.4) 74 (59.7) 39 (31.5)
Diarrhea 57 (52.8) 7 (6.5) 65 (52.4) 8 (6.5)
Fatigue 56 (51.9) 9 (8.3) 59 (47.6) 9 (7.3)
Decreased appetite 51 (47.2) 0 59 (47.6) 0
Hypothyroidismc 48 (44.4) 1 (0.9) 54 (43.5) 1 (0.8)
Nausea 43 (39.8) 3 (2.8) 48 (38.7) 3 (2.4)
Stomatitis 36 (33.3) 0 39 (31.5) 0
Pain and arthralgiad 34 (31.5) 2 (1.9) 37 (29.8) 2 (1.6)
Dysphonia 30 (27.8) 0 34 (27.4) 0
PPE and severe skin reactionse 29 (26.9) 5 (4.6) 32 (25.8) 6 (4.8)
Vomiting 29 (26.9) 0 31 (25.0) 0
Weight decreased 28 (25.9) 2 (1.9) 30 (24.2) 2 (1.6)
Proteinuriaf 24 (22.2) 4 (3.7) 30 (24.2) 4 (3.2)
Headache 22 (20.4) 0 25 (20.2) 0
Myalgia 19 (17.6) 1 (0.9) 20 (16.1) 1 (0.8)
Hepatotoxicity and hepatitisg 16 (14.8) 3 (2.8) 21 (16.9) 4 (3.2)
Hypomagnesemia 16 (14.8) 2 (1.9) 18 (14.5) 2 (1.6)
Abdominal pain and upper abdominal painh 15 (13.9) 2 (1.9) 17 (13.7) 2 (1.6)
Asthenia 14 (13.0) 6 (5.6) 19 (15.3) 7 (5.6)
Hemorrhagei 14 (13.0) 3 (2.8) 19 (15.3) 4 (3.2)
Lipase increased 12 (11.1) 7 (6.5) 13 (10.5) 7 (5.6)
QT prolongation and cardiac dysfunctionj 10 (9.3) 2 (1.9) 10 (8.1) 2 (1.6)
Dehydration 9 (8.3) 1 (0.9) 9 (7.3) 1 (0.8)
Renal events and nephritisk 9 (8.3) 2 (1.9) 9 (7.3) 2 (1.6)
Dyspnea 8 (7.4) 1 (0.9) 8 (6.5) 1 (0.8)
Oral pain 8 (7.4) 1 (0.9) 8 (6.5) 1 (0.8)
Confusional state and deliriuml 7 (6.5) 4 (3.7) 7 (5.6) 4 (3.2)
Hyponatremia 7 (6.5) 5 (4.6) 7 (5.6) 5 (4.0)
Hypokalemia 5 (4.6) 1 (0.9) 6 (4.8) 2 (1.6)
Anemia 5 (4.6) 1 (0.9) 5 (4.0) 1 (0.8)
Adrenal insufficiencym 4 (3.7) 3 (2.8) 4 (3.2) 3 (2.4)
Amylase increased 4 (3.7) 2 (1.9) 4 (3.2) 2 (1.6)
Colitisn 4 (3.7) 2 (1.9) 4 (3.2) 2 (1.6)
Pancreatitiso 4 (3.7) 1 (0.9) 4 (3.2) 1 (0.8)
Pulmonary embolism 4 (3.7) 4 (3.7) 4 (3.2) 4 (3.2)
Hypotension 3 (2.8) 1 (0.9) 3 (2.4) 1 (0.8)
Syncope 3 (2.8) 2 (1.9) 3 (2.4) 2 (1.6)
Hypertriglyceridemia 2 (1.9) 0 3 (2.4) 1 (0.8)
Arterial TE eventsp 2 (1.9) 1 (0.9) 2 (1.6) 1 (0.8)
Colitis ischemic 2 (1.9) 2 (1.9) 2 (1.6) 2 (1.6)
Hyperkalemia 2 (1.9) 1 (0.9) 2 (1.6) 1 (0.8)
(continued on following page)
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treatments; and n = 1, 36 treatments [allowable before
protocol amendment 4]).
This study is limited by its nonrandomized nature. More-
over, exploratory analyses regarding PD-L1 status should
be viewed with caution, as the cutoff for PD-L1 positivity is
not definitive, and it is not known if PD-L1 status is a positive
prognostic indicator in endometrial cancer. Additional
limitations include the absence of a quality-of-life analysis
as well as a lack of biomarker assessments to characterize
patients susceptible to checkpoint inhibitors (ie, tumor
mutational burden and mutation-associated neoantigens);
however, biomarker analyses are planned. It should be
noted that although this trial may be considered small, its
size (key efficacy analysis, n = 108; overall population,
n = 124) is comparable to the collective size of trials that
led to the approval of pembrolizumab in patients with
MSI-H cancers (n = 149).39
Overall, the results of this study are encouraging and
showed compelling efficacy and an acceptable safety
profile in patients with advanced endometrial carcinoma.
As a result of this study, lenvatinib plus pembrolizumab was
granted accelerated approval for the treatment of patients
TABLE 3. Treatment-Related Adverse Events ($ 20% any grade or any grade 3 or grade 4 events) (continued)
Preferred Term or Basket
Previously Treated ECa (n = 108) All EC (N = 124)
Any Grade Grade 3/4 Any Grade Grade 3/4
Small intestinal obstruction 2 (1.9) 1 (0.9) 2 (1.6) 1 (0.8)
GI perforationq 1 (0.9) 1 (0.9) 2 (1.6) 2 (1.6)
Cholecystitis acute 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Dysarthria 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Escherichia sepsis 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Hypocalcemiar 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Hypophysitiss 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Neutropenia 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Pelvic abscess 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Pneumothorax 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
Rectal ulcer 1 (0.9) 1 (0.9) 1 (0.8) 1 (0.8)
NOTE. Data are presented as No. (%). Patients are counted in the worst grade experienced of grade 3 or 4.
Abbreviations: AE, adverse event; EC, endometrial carcinoma; PPE, palmar-plantar erythrodysesthesia; TE, thromboembolism; TEAEs,
treatment-emergent adverse events.
aEnrolled before July 1, 2018.
bHypertension basket (preferred terms: hypertensive encephalopathy, essential hypertension, hypertension).
cHypothyroidism basket (preferred terms: hypothyroidism and blood thyroid-stimulating hormone increased).
dCombines 2 preferred terms: pain and arthralgia.
eCombines PPE basket (preferred term: PPE syndrome) with severe skin reactions basket (preferred terms: exfoliative rash, rash
maculopapular, rash pruritic).
fProteinuria basket (preferred term: proteinuria).
gCombines hepatotoxicity basket (preferred terms: ascites, autoimmune hepatitis, hepatitis, hyperbilirubinemia, jaundice, alanine
aminotransferase increase, AST increased, blood alkaline phosphatase increased, blood bilirubin increased, transaminases increased,
hypoalbuminemia, encephalopathy, metabolic encephalopathy) and hepatitis basket (preferred terms: autoimmune hepatitis and hepatitis).
hCombines 2 preferred terms: abdominal pain and upper abdominal pain.
iHemorrhage basket term (preferred terms: GI hemorrhage, gingival bleeding, hematemesis, hematochezia, large intestinal hemorrhage,
mouth hemorrhage, upper GI hemorrhage, catheter site bruise, injection site hemorrhage, contusion, hemorrhage intracranial, intraventricular
hemorrhage, hematuria, coital bleeding, metrorrhagia, uterine hemorrhage, vaginal hemorrhage, epistaxis, hematoma).
jQT prolongation basket (preferred term: electrocardiogram QT prolonged).
kCombines renal events basket (preferred term: blood creatinine increased, acute kidney injury, nephritis, renal failure, renal vein thrombosis)
and nephritis basket (preferred term: autoimmune nephritis, nephritis).
lCombines 2 preferred terms: confusional state and delirium.
mAdrenal insufficiency basket (preferred term: adrenal insufficiency).
nColitis basket (preferred term: colitis).
oPancreatitis basket (preferred terms: pancreatitis, pancreatitis acute).
pArterial TE events basket (preferred terms: cerebral ischemia, ischemic cerebral infarction, transient ischemic attack).
qGI perforation basket (preferred terms: gastric perforation, GI perforation, large intestine perforation, abdominal abscess).
rHypocalcemia basket (preferred term: hypocalcemia).
sHypophysitis basket (preferred term: hypopituitarism).
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with advanced endometrial carcinoma that is not MSI-H
or dMMR, who have disease progression after prior
systemic therapy, and who are not candidates for curative
surgery or radiation.40 In addition, two phase III trials of
lenvatinib plus pembrolizumab in advanced endometrial
carcinoma are currently underway (ClinicalTrials.gov
identifier: NCT03884101 [v carboplatin plus paclitaxel in
the first-line setting] and ClinicalTrials.gov identifier:
NCT03517449 [v doxorubicin or paclitaxel in previously
treated patients]).
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